Clinical trials: Capecitabine
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Capecitabine in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating patients who have recurrent…
- Trial name
- NCT00006812
- Testing
- capecitabine
- Where
- 31 sites in United States, Canada
- Sponsor
- Gynecologic Oncology Group
Advanced Non-Small Cell Lung Cancer
The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer
The purpose of this study is to compare the overall survival of patients with advanced non small cell lung cancer treated with docetaxel as single therapy versus docetaxel in combination with either gemcitabine or vinorelbine or…
- Trial name
- DISTAL-2 (NCT00345059)
- Testing
- docetaxel, vinorelbine, gemcitabine
- Where
- 24 sites in Italy
- Volunteers
- 84 people
- Sponsor
- National Cancer Institute, Naples
Rectal Cancer, Rectal Adenocarcinoma
Factors Predicting Recurrence in Rectal Cancer After Surgery
Colorectal cancer is one of the most frequently diagnosed cancers and a major cause of cancer deaths worldwide. Recurrence after curative surgery is one of the major factors affecting the long-term survival and its frequency is…
- Trial name
- NCT03899870
- Testing
- Rectal resection, Neoadjuvant therapy, Adjuvant therapy
- Volunteers
- 188 people
- Sponsor
- ammar houssem
Hepatocellular Carcinoma
Transarterial Chemotherapy Compared With Oral Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma
In India, majority of our patients have advanced hepatocellular carcinoma (HCC) at presentation and hence are unsuitable for the available curative treatment options. In such patients the treatment options are mainly palliative.
- Trial name
- NCT02240771
- Testing
- Transarterial chemotherapy, Oral chemotherapy
- Where
- India
- Volunteers
- 124 people
- Sponsor
- All India Institute of Medical Sciences
Metastatic Breast Cancer
Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study
Women with recurrent or metastatic breast cancer who are hormone receptor positive are candidates for first line hormonal therapy including aromatase inhibitors.
- Trial name
- CONCEPT (NCT04012918)
- Testing
- Capecitabine plus aromatase inhibitor, A.I.
- Where
- Egypt
- Volunteers
- 124 people
- Sponsor
- Ain Shams University
Breast Cancer Stage IV
RWS of Paclitaxel Liposome Combined With Anti-HER-2 Monoclonal Antibody
This is a retrospective, single-arm real-world study based on the National Anticancer Drug Clinical Application Monitoring Network database.The aim of this study is to evaluate the efficacy and safety of paclitaxel liposome…
- Trial name
- NCT06481553
- Testing
- first line treatment
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Cancer
Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer
Primary Objectives: Determine the impact of each regimen on the disease free and overall survival of patients with operable breast cancer.
- Trial name
- NCT00050167
- Testing
- Paclitaxel, Docetaxel, Capecitabine
- Where
- United States
- Volunteers
- 603 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Neoplasms Malignant
The Effects of RFA in Combination With Second-line Chemotherapy and Bevacizumab on Unresectable CRLM
Basing on the strong evidence from former researches, patients with CRLM can benefit from the treatment of bevacizumab combined with sencond-line chemotherapy.
- Trial name
- NCT03686254
- Testing
- RFA, bevacizumab and second-line chemotherapy, Bevacizumab and second-line chemotherapy
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Breast Cancer
BREAST-10: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer
Some chemotherapies, including docetaxel, are better tolerated and just as effective when giving the dose weekly rather than on an every three week basis.
- Trial name
- BREAST-10 (NCT00540800)
- Testing
- docetaxel, epirubicin, capecitabine
- Where
- 3 sites in Italy
- Volunteers
- 139 people
- Sponsor
- National Cancer Institute, Naples
Breast Cancer
Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer
This trial studies the effects on quality of life and on time to second progression of the sequence endocrine therapy-capecitabine versus the sequence capecitabine-endocrine treatment.
- Trial name
- NCT00684216
- Testing
- capecitabine, hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole)
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- The Netherlands Cancer Institute
Cholangiocarcinoma
Evaluation of Combined Modality Protons and Hepatic Transplantation for Hilar Cholangiocarcinoma
Proton Beam Therapy (PBT) is an advanced radiotherapy technique. There are two National Health Service (NHS) PBT treatment centres in the United Kingdom (UK), in Manchester and London.
- Trial name
- EMPHATIC (NCT06434493)
- Testing
- Proton Beam Therapy, Concurrent oral capecitabine chemotherapy, Cisplatin & Gemcitabine intravenous chemotherapy
- Volunteers
- 30 people
- Sponsor
- The Christie NHS Foundation Trust
Biliary Tract Cancer
Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer
This protocol for Varlitinib is developed for the treatment of Biliary Tract Cancer. Varlitinib (also known as ASLAN001) is a small-molecule, adenosine triphosphate competitive inhibitor of the tyrosine kinases - epidermal growth…
- Trial name
- TreeTopp (NCT03093870)
- Testing
- Varlitinib, Capecitabine
- Where
- 21 sites in United States, Australia and 9 more
- Volunteers
- 151 people
- Sponsor
- ASLAN Pharmaceuticals
Breast Neoplasms, Metastases, Neoplasm
Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients
The primary objective of the phase I study is to determine a safe dose for combination therapy with capecitabine and exisulind. A secondary objective is to assess pharmacokinetic interactions between the two drugs and assess the…
- Trial name
- NCT00037609
- Testing
- Capecitabine, Exisulind
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Neoplasms
A Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Maintenance Treatment With Capecitabine Plus Cetuximab in Metastatic Colorectal Cancer
This is a single arm, open-label, multi-center clinical trial to evaluate the efficacy and safety of maintenance treatment with capecitabine plus cetuximab after first-line 5-fluorouracil-based chemotherapy plus cetuximab for…
- Trial name
- NCT02717923
- Testing
- maintenance treatment with capecitabine plus cetuximab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Huazhong University of Science and Technology
Cervical Cancer
Capecitabine in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating patients who have advanced…
- Trial name
- NCT00016926
- Testing
- capecitabine
- Where
- 10 sites in United States, Norway
- Sponsor
- Gynecologic Oncology Group
Rectal Cancer, Oncology
Outcomes of Neoadjuvant Therapy for Rectal Cancer in a Tertiary Asian Institute
This is a retrospective cohort study that aims to evaluate the correlation of magnetic resonance tumour regression grade (mrTRG) and pathological TRG (pTRG) of locally advanced rectal cancer after neoadjuvant long course…
- Trial name
- NCT05607186
- Testing
- neoadjuvant long course chemoradiotherapy
- Volunteers
- 59 people
- Sponsor
- Singapore General Hospital
Colorectal Cancer
Leucovorin and Fluorouracil With or Without Oxaliplatin Compared to Capecitabine With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as leucovorin, fluorouracil, capecitabine, and oxaliplatin, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00070213
- Testing
- FOLFOX regimen, capecitabine, fluorouracil
- Where
- 4 sites in United Kingdom
- Volunteers
- 460 people
- Sponsor
- Medical Research Council
Pan-tumor
ONO-4538 Phase II Rollover Study (ONO-4538-98)
This study is intended to confirm the long-term safety of ONO-4538 in pan-tumor participants being treated with ONO-4538 monotherapy or in Combination with Other Therapies in clinical trials.
- Trial name
- NCT04566380
- Testing
- ONO-4538, oxaliplatin, S-1
- Where
- 44 sites in Japan, South Korea and 1 more
- Volunteers
- 70 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Breast Cancer Female
Young Patients With Early Breast Cancer
The prognosis of young patients with breast cancer is relatively poor. Chemotherapy damages ovarian function. Endocrine treatment for up to 10 years delays the childbearing time of patients.
- Trial name
- NCT06027541
- Testing
- operation
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Peking Union Medical College Hospital
Locally Advanced Rectal Cancer
The Combination of Immunotherapy and Neoadjuvant Chemoradiotherapy in MSI-H Locally Advanced Rectal Cancer
The study evaluates the addition of immunotherapy of PD-1 antibody in neoadjuvant chemoradiotherapy in microsatellite stability-high (MSI-H) locally advanced rectal cancer (LARC).
- Trial name
- NCT04411524
- Testing
- PD-1 antibody, Capecitabine, Irinotecan
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University